About: Elective procedures for prostate cancer in the time of Covid-19: a multidisciplinary team experience

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Elective procedures for prostate cancer in the time of Covid-19: a multidisciplinary team experience Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Elective procedures for prostate cancer in the time of Covid-19: a multidisciplinary team experience
Creator	Catalano, Carlo Musio, Daniela Panebianco, Valeria Sciarra, Alessandro Busetto, Maria Ciardi, • Cortesi, Enrico Gian, • Giudice, Francesco Maggi, Martina Salciccia, Stefano
Source	Medline; PMC
abstract	On March 29th 2020, 97,689 cases of COVID-19 have been diagnosed only in Italy, with 73,880 actually positive cases, a daily increase of 3815 cases, 27,386 hospitalized and 3906 patients in intensive care units, causing a total of 10,779 known deaths. In all urological departments, quickly inpatient and outpatient services have been significantly reduced. Even in this COVID-19 situation, urological neoplasm care must go on, but significant changes need to be made in the way some care is delivered. We compared diagnostic and therapeutic elective procedures requested and performed for PC management from our multidisciplinary team (MDT) during 1 month activity in the highest national level of COVID-19 infection (March 2020) and under restrictions for all the population, with the management performed in a no-COVID-19 month (March 2019) 1 year ago. The only management that did not received a significant reduction are medical therapies for advanced hormone sensitive (HS) or castration resistant (CR) PC. We describe our MDT identifications of elective undeferrable PC management in this COVID-19 time. These suggestions have been considered for a country (ITALY) under a rapid increase of COVID-19 cases and complications, but in a region with an actual lower impact (2914 actual positive and 1079 hospitalized cases) from the infection and in an hospital not completely converted to COVID-19 management. Indications should be different and restricted only to emergencies on the basis of COVID-19 pandemic situation and hospital involvement.
has issue date	2020-05-18(xsd:dateTime)
bibo:doi	10.1038/s41391-020-0240-4
bibo:pmid	32425655
has license	no-cc
sha1sum (hex)	7ef104e03ab7fc5204c09a3b7deecdfa917df963
schema:url	https://doi.org/10.1038/s41391-020-0240-4
resource representing a document's title	Elective procedures for prostate cancer in the time of Covid-19: a multidisciplinary team experience
has PubMed Central identifier	PMC7233331
has PubMed identifier	32425655
schema:publication	Prostate Cancer Prostatic Dis
resource representing a document's body	covid:7ef104e03ab7fc5204c09a3b7deecdfa917df963#body_text
is schema:about of	named entity 'March' named entity 'infection' named entity 'cases' named entity 'Even' named entity 'management' named entity 'COVID-19' named entity 'Diseases' named entity 'ACTUAL' named entity 'WAY' named entity 'HIGHEST' named entity 'REDUCTION' named entity 'MDT' named entity 'BASIS' named entity 'INCREASE' covid:arg/7ef104e03ab7fc5204c09a3b7deecdfa917df963 named entity 'restrictions' named entity 'MDT' named entity 'time' named entity 'requested' named entity 'urological' named entity 'hormone' named entity 'multidisciplinary team' named entity '19 management' named entity 'completely' named entity 'intensive care units' named entity 'services' named entity 'COVID' named entity 'March 2020' named entity 'neoplasm' named entity 'COVID' named entity 'medical therapies' named entity 'elective procedures' named entity 'COVID' named entity '19 management' named entity 'multidisciplinary team' named entity 'prostate cancer' named entity 'early diagnosis' named entity 'March 2020' named entity 'Student's t test' named entity 'COVID-19 pandemic' named entity 'neoadjuvant' named entity 'MDT' named entity 'radiotherapy' named entity 'coronavirus 2' named entity 'COVID' named entity 'castration resistant' named entity 'COVID' named entity 'infection' named entity 'prostate biopsy' named entity 'COVID' named entity 'co-morbidities' named entity 'elective procedures' named entity 'radiotherapy' named entity 'infection' named entity 'infection' named entity 'androgen receptor' named entity 'CRPC' named entity 'COVID' named entity 'COVID' named entity 'Northern Italy' named entity 'chemotherapy' named entity 'Italian' named entity 'COVID' named entity 'infection' named entity 'anesthesiologists' named entity 'Italy' named entity 'oncologic criteria' named entity 'radiotherapy' named entity 'Outpatient' named entity 'biopsy' named entity 'COVID-19 disease'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software